Holen Sie sich die Stockscreener-App
0.6768
3.33%
0.0218
Vorhandelsmarkt:
.68
0.0032
+0.47%
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
Earnings Recap: Is Oragenics Inc gaining market shareWeekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn
Oragenics Doses First Patient in Phase IIa Trial for Potential Concussion Treatment - citybuzz -
Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia - TipRanks
Oragenics Doses First Patient in Phase IIa Trial of ONP-002 for Concussion, Targeting Unmet Need in Mild Traumatic Brain Injury 1 - Minichart
Oragenics doses first patient in Phase IIa trial of ONP-002 for concussion - TradingView — Track All Markets
With no approved concussion drug, Oragenics starts patient dosing - Stock Titan
Sectors Review: Is Oragenics Inc stock technically oversold2026 Institutional & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Oragenics (OGEN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Nasdaq Moves: Is Oragenics Inc vulnerable to short sellersQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Risk On: Is Oragenics Inc gaining market sharePrice Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Rally Mode: Is Oragenics Inc gaining market share2026 Trading Volume Trends & Long-Term Capital Growth Strategies - baoquankhu1.vn
0A64.IL,0P0001LL1F,111 (0A64.IL) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Oragenics Inc (UAV.BE) Stock Price, News, Quote & History - ca.finance.yahoo.com
OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics Sets New 2025 Annual Shareholder Meeting Date - The Globe and Mail
Oragenics: CEO Highlights "Undervalued" Pipeline Amid Significant Insider Sale of 35% Ownership - Bitget
Oragenics (OGEN) schedules 2025 shareholder meeting and sets May 1, 2026 proposal cutoff - Stock Titan
Risks Report: What is the target price for Oragenics Inc stockDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations - citybuzz -
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - Sahm
Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - GuruFocus
OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan
Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
[EFFECT] ORAGENICS INC SEC Filing - Stock Titan
If You Invested $1,000 in Oragenics (OGEN) - Stock Titan
Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Oragenics, Inc.: Fundamental Analysis and Financial Ratings | UAV0 | US6840236094 - marketscreener.com
OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan
Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times
Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - Sahm
Oragenics Initiates First Clinical Site for Phase IIa Trial of Intranasal Concussion Treatment - citybuzz -
Oragenics Inc Initiates Phase Iia Clinical Trial Site Activation - marketscreener.com
Oragenics (OGEN) Advances Phase IIa Clinical Trial of ONP-002 in Australia - GuruFocus
Oragenics begins testing nasal concussion treatment in Australia - Stock Titan
Oragenics Receives Australian HREC Approval to Begin Phase IIa Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury - Minichart
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions - TipRanks
Oragenics Explores CNS Asset Acquisitions to Expand Brain Health Pipeline - citybuzz -
Oragenics (OGEN) Eyes Expansion in Central Nervous System Sector - GuruFocus
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - The Manila Times
Oragenics Explores Expansion of CNS Platform - Moomoo
Oragenics (OGEN) Receives Approval for Phase IIa Concussion Drug Trial in Australia - GuruFocus
Oragenics Receives HREC Approval for Phase IIa Clinical - GlobeNewswire
Is Oragenics Inc forming bullish engulfing patterns2025 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Inflation Data: Is Oragenics Inc a strong candidate for buy and holdJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Aug Technicals: What is the target price for Oragenics Inc stockPortfolio Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
OGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Momentum Shift: Is Oragenics Inc vulnerable to short sellersJuly 2025 Update & Weekly Breakout Stock Alerts - baoquankhu1.vn
How Oragenics Inc. stock trades pre earningsJuly 2025 Pullbacks & Risk Managed Investment Entry Signals - mfd.ru
OGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
OGEN Should I Buy - Intellectia AI
Can Oragenics Inc. sustain its profitabilityJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
Is Oragenics Inc. vulnerable to short sellers2025 Key Lessons & Verified Chart Pattern Signals - mfd.ru
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):